Irbesartan and Amlodipine Combination in Controlling Blood Pressure

NCT ID: NCT00950066

Last Updated: 2011-01-05

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 270 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2009-07-31
• Study Completion Date: 2010-01-31

Brief Summary

The primary objective is to compare the extent of reduction of mean Seated Diastolic Blood Pressure (SeDBP) at the end of 8 weeks between each Fixed Dose Combination (FDC), its individual constituents administered as monotherapy and placebo.

The secondary objectives are:

• to compare the reduction of mean Seated Systolic Blood Pressure (SeSBP) at the end of 8 weeks from baseline between each FDC, its individual constituents administered as monotherapy and placebo.
• to compare the reduction of mean SeDBP and SeSBP at 4 weeks from baseline between each FDC, its individual constituents administered as monotherapy and placebo.

Conditions

Hypertension

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: TRIPLE

Study Groups

Placebo

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with placebo once a day.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: DRUG

Oral administration of a placebo once a day

Irbesartan 150mg

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with Irbesartan 150 mg once a day.

Group Type: ACTIVE_COMPARATOR

IRBESARTAN (SR47436)

Intervention Type: DRUG

Oral administration of Irbesartan 150mg or 300mg once a day

Irbesartan 150 mg / Amlodipine 5 mg

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with Irbesartan 150 mg / Amlodipine 5 mg once a day.

Group Type: ACTIVE_COMPARATOR

Irbesartan / Amlodipine

Intervention Type: DRUG

Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day

Amlodipine

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with Amlodipine 5 mg once a day.

Group Type: ACTIVE_COMPARATOR

Amlodipine

Intervention Type: DRUG

Oral administration of Amlodipine 5mg once a day

Irbesartan 300 mg

Active Comparator: Irbesartan

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with Irbesartan 300 mg once a day.

Group Type: ACTIVE_COMPARATOR

IRBESARTAN (SR47436)

Intervention Type: DRUG

Oral administration of Irbesartan 150mg or 300mg once a day

Irbesartan 300 mg / Amlodipine 5 mg

Before randomization (common with other arms):

There is an initial washout (placebo run-in) period of 2 weeks for subjects already on anti-hypertensive monotherapy.

After randomization:

8 weeks of treatment with Irbesartan 300 mg / Amlodipine 5 mg once a day.

Group Type: ACTIVE_COMPARATOR

Irbesartan / Amlodipine

Intervention Type: DRUG

Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day

Interventions

IRBESARTAN (SR47436)

Oral administration of Irbesartan 150mg or 300mg once a day

Intervention Type: DRUG

Amlodipine

Oral administration of Amlodipine 5mg once a day

Intervention Type: DRUG

Irbesartan / Amlodipine

Oral administration of Irbesartan 150 mg / Amlodipine 5mg or Irbesartan 300mg / Amlodipine 5mg once a day

Intervention Type: DRUG

Placebo

Oral administration of a placebo once a day

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Subjects with uncomplicated mild to moderate essential hypertension (as per European Society of Cardiology Classification of Hypertension)

• Treatment naïve subjects (newly diagnosed subjects or subjects currently only on lifestyle modification) with mean SeDBP of 95 to 109 mmHg at both screening and randomization visit (mean of 3 recordings at intervals of 1 minute) Or
• Uncontrolled on any anti-hypertensive monotherapy and with mean SeDBP of 90 to 109 mmHg at screening and mean SeDBP of 95 to 109 mmHg at the randomization visit (mean of 3 recordings at intervals of 1 minute).
• Signed written informed consent obtained prior to inclusion in the study.
• Subjects willing to adhere to protocol and study requirements during the entire study duration.
• Subjects having no abnormalities in general physical examination.

Exclusion Criteria

• Subjects who are incapable of giving informed consent for the study.
• Subjects with SeDBP > or = 110mmHg and / or SeSBP > or = 180 mmHg measured at Doctor's office during screening or randomization visit
• Subjects having a difference of > 8 mmHg between any 2 of the 3 SeDBP measurements either at screening or at randomization.
• Subjects who are on any anti-hypertensive therapy and unable to discontinue the anti-hypertensive therapy safely for a period of at least 2 weeks as required by the protocol.
• Subjects who cannot be discontinued on medications prohibited by the protocol.
• Subjects on combination therapies for treatment of hypertension.
• Subjects with known documented secondary hypertension including (but not limited to) hypertension secondary to coarctation of aorta, hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's disease, pheochromocytoma, polycystic kidney disease, etc.
• Subjects with known diabetes (Type 1 or Type 2).
• Subjects with known documented complications of hypertension including (but not limited to):

• Cardiovascular disease: Ischemic heart disease (angina, myocardial infarction), heart failure, peripheral vascular disease.
• Cerebrovascular disease: Stroke, cerebral hemorrhage.
• Ophthalmic: Retinal hemorrhage, impaired vision, retinal microaneurysms.
• Subjects with known severe renal impairment (creatinine clearance < 30 ml/min) calculated using the Cockcroft-Gault equation.
• Subjects with hyperkalemia (>5.1mmol/L) and/or hyponatremia (<133mmol/L).
• Subjects with known severe hepatic impairment (alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3 times the upper limit of normal or history of hepatic encephalopathy, esophageal varices, or portocaval shunt.
• Subjects with clinically significant abnormalities on ECG
• Subjects with any other clinical condition which, in the opinion of the Investigator, might interfere with administration of Irbesartan or Amlodipine and evaluation of the study objectives.
• Subjects with known history of allergy considered due to any of the study drugs or their components, including excipients (lactose) and preservatives.
• Subjects with known history of substance abuse (drug or alcohol dependency, alcohol, if not stopped, <20gms per day will be allowed during the study period).
• Subjects known positive for HIV 1 or 2 virus.
• Subjects with known or suspected impairment of the immune function, and/or receiving immunosuppressive therapy, or having received immunosuppressive therapy within 30 days prior to study entry.
• Subjects who have received any other investigational drug within 30 days before inclusion.
• Pregnant (demonstrating a positive serum (ß-HCG) pregnancy test at screening visit) or lactating female subjects.
• Subjects and partners unwilling to employ adequate contraception during the course of the study.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Sanofi

INDUSTRY

Sponsor Role: lead

Responsible Party

sanofi-aventis

Principal Investigators

Sanjay Aggarwal, MD

Role: STUDY_DIRECTOR

Sanofi

Locations

Sanofi-Aventis Administrative Office

Mumbai, , India

Sanofi-Aventis Administrative Office

Makati City, , Philippines

Sanofi-Aventis Administrative Office

Seoul, , South Korea

Sanofi-Aventis Administrative Office

Taipei, , Taiwan

Countries

India; Philippines; South Korea; Taiwan

Other Identifiers

IRBES_R_04320

Identifier Type: -

Identifier Source: org_study_id